Through a global rights agreement with Futuregen Biopharmaceutical Co. Ltd., Abbvie Inc. continues to build its immunology portfolio to help offset losses from Humira as biosimilars tighten their grip on the mega-blockbuster.
Through a global rights agreement with Futuregen Biopharmaceutical Co. Ltd., Abbvie Inc. continues to build its immunology portfolio to help offset losses from Humira as biosimilars tighten their grip on the mega-blockbuster.
Abbvie Inc. and Futuregen Biopharmaceutical (Beijing) Co. Ltd. have signed a license agreement to develop FG-M701, a next-generation TL1A antibody for the treatment of inflammatory bowel disease.
